ACHN-490, a Neoglycoside with Potent In Vitro Activity against Multidrug-Resistant Klebsiella pneumoniae Isolates

Abstract
The in vitro activity of ACHN-490, a novel aminoglycoside ("neoglycoside"), was evaluated against 102 multidrug-resistant (MDR) Klebsiella pneumoniae strains, including a subset of 25 strains producing the KPC carbapenemase. MIC50 values for gentamicin, tobramycin, and amikacin were 8 mu g/ml, 32 mu g/ml, and 2 mu g/ml, respectively; MIC90 values for the same antimicrobials were >= 64 mu g/ml, >= 64 mu g/ml, and 32 mu g/ml, respectively. ACHN-490 showed an MIC50 of 0.5 mu g/ml and an MIC90 of 1 mu g/ml, which are significantly lower than those of comparator aminoglycosides. ACHN-490 represents a promising aminoglycoside for the treatment of MDR K. pneumoniae isolates, including those producing KPC beta-lactamase.

This publication has 24 references indexed in Scilit: